104. A Host Based Genomic Paradigm for the Early Detection and Classification of Infectious Disease
Session: Symposium: Genomic Tools for Personalized Infectious Diseases Management and Outbreak Investigations
Thursday, October 3, 2013: 11:30 AM
Room: The Moscone Center: 135 (Hall E)
Geoffrey S. Ginsburg, MD, PhD, Director, Center For Genomic Medicine In The Duke Institute For Genome Sciences & Policy, Duke University, Durham, NC

Geoffrey S Ginsburg, MD, PhD Director, Center for Genomic Medicine, Duke Institute for Genome Sciences & Policy, and Professor of Medicine and Pathology, Duke University Medical Center Dr Ginsburg, a founding director of the Center for Genomic Medicine, assumed his current position in the Duke Institute for Genome Sciences and Policy in 2004 and was also appointed as co-director of the Duke Translational Medicine Institute in 2006. While at Duke, Dr Ginsburg has pioneered translational genomics, initiating the first genomic-guided clinical trials as well as developing novel practice models for deploying genomic tools in heath care systems. The center focuses on oncology, infectious diseases, cardiovascular disease and metabolic disorders. In 1990, he joined the faculty of Harvard Medical School, where he was director of preventive cardiology, and led a laboratory in applied genetics of cardiovascular disease. In 1997 he joined Millennium Pharmaceuticals Inc, as senior program director for cardiovascular diseases and was eventually appointed vice president of Molecular and Personalized Medicine at Millennium, where he was responsible for developing pharmacogenomic strategies for therapeutics, as well as biomarkers for disease and their implementation in the drug development process. Dr Ginsburg research interests are in the development of novel paradigms for developing and translating genomic information into medical practice and the integration of personalized medicine into health care. He has received a number of awards for his research accomplishments, including the Innovator in Medicine Award from Millennium in 2004 and the Basic Research Achievement Award in Cardiovascular Medicine from Duke in 2005. He is a founding member of the Personalized Medicine Coalition, a senior consulting editor for The Journal of the American College of Cardiology, editor-in-chief for The HUGO Journal, and an editorial advisor for Science Translational Medicine. He has been an international expert panel member for Genome Canada and is currently a member of the Board of External Experts for the National Heart, Lung and Blood Institute, the Secretary of Veterans Affairs Advisory Council on Genomic Medicine and the Institute of Medicine’s Roundtable on Genome-Based Research to Human Health. Recently, he was appointed to the National Advisory Council for Human Genome Research and is a nominee to the FDA’s Advisory Committee for Clinical Pharmacology. He received his MD and PhD in biophysics from Boston University and completed an internal medicine residency at Beth Israel Hospital in Boston, MA. Subsequently, he pursued postdoctoral training in clinical cardiovascular medicine at Beth Israel Hospital and in molecular biology at Children’s Hospital as a Bugher Foundation Fellow of the American Heart Association.



<< Previous Presentation | Next Presentation

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.